Monatepil
Names | |
---|---|
Preferred IUPAC name
N-(6,11-Dihydrodibenzo[b,e]thiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChemSpider |
|
KEGG |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula |
C28H30FN3OS |
Molar mass | 475.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
N verify (what is YN ?) | |
Infobox references | |
Monatepil is a calcium channel blocker and α1-adrenergic receptor antagonist used as an antihypertensive.[1]
References
- ↑ Sugimoto T, Hosoki K, Karasawa T (July 1995). "Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil". Journal of Cardiovascular Pharmacology. 26 (1): 55–60. doi:10.1097/00005344-199507000-00009. PMID 7564365.
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
---|---|---|---|---|---|
Other antagonists |
| ||||
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |
Adrenergic receptor modulators | |||||
---|---|---|---|---|---|
α1 |
| ||||
α2 |
| ||||
β |
| ||||
|
Classes |
|
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.